Mark T Drayson

11PUBLICATIONS
58CO-AUTHORS
Molecular targetsInnate immunityPredictive and prognostic markersMedical biotechnology diagnostics (incl. biosensors)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Oct 10, 2024
Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia.

Richard Harrop, Daniel G Blount, Naeem Khan

|Sep 07, 2024
Plasma cell disorders supress mucosal anti-bacterial immunity: another dimension of immunoparesis in plasma cell neoplasms.

Sian Faustini, Y L Tracey Chan, Lilli Evans

|Mar 19, 2024
Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry.

H V Giles, M T Drayson, B Kishore

|Jan 03, 2024
Laboratory practice is central to earlier myeloma diagnosis: Utilizing a primary care diagnostic tool and laboratory guidelines integrated into haematology services.

Mark Drayson, Tom Jennis, Ira Laketic-Ljubojevic

|Dec 20, 2023
Determinants of durable humoral and T cell immunity in myeloma patients following COVID-19 vaccination.

Clement Twumasi, Sally Moore, Ross Sadler

|Jul 14, 2023
Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial.

Stella Bowcock, Catherine Atkin, Gulnaz Iqbal

Pageof 2

Frequent Collaborators

5 joint publications

Guy Pratt

3 joint publications

Gordon Cook

3 joint publications

Stella Bowcock

2 joint publications

Kamaraj Karunanithi